Chi Van Dang

Chi Van Dang

Auto-generated profile, based on publicly available information

Chi Van Dang

Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Cell Metabolism
Verified
Journal Article
Closed access
JKJung-whan Kim
Jung-whan Kim
ITIrina Tchernyshyov
Irina Tchernyshyov
GSGregg L. Semenza
Gregg L. Semenza
CDChi V. Dang
Chi V. Dang

1 March 2012 in Cell
Verified
Journal Article
Closed access
CDChi V. Dang
Chi V. Dang

14 April 2011 in Nature Reviews Cancer
Verified
Journal Article
Closed access
WKWillem H. Koppenol
Willem H. Koppenol
PBPatricia L. Bounds
Patricia L. Bounds
CDChi V. Dang
Chi V. Dang

9 June 2005 in Nature
Verified
Journal Article
Open access
PDF file
KOKathryn A. O'DOnnell
Kathryn A. O'DOnnell
EWErik A. Wentzel
Erik A. Wentzel
KZKaren I. Zeller
Karen I. Zeller
CDChi V. Dang
Chi V. Dang
JMJoshua T. Mendell
Joshua T. Mendell
MicroRNAs are regulatory, non-coding RNAs about 22 nucleotides in length: over 200 have been identified in humans, and their functions are beginning to be pinned down. It has been suggested that like other regulatory molecules they might be involved in tumour formation, and three papers in this issue confirm that this is the case. One cluster of microRNAs, known as mir-17–92, is shown to be a potential oncogene by its action in an in vivo model of human B-cell lymphoma. A cluster of microRNAs on human chromosome 13 has been found to be regulated by c-Myc, an important transcription factor that is overexpressed in many human cancers. And analysis of microRNA expression in over 300 individuals shows that microRNA profiles could be of value in cancer diagnosis. There is a global downregulation of microRNA in tumours, and the microRNA profile also reflects the origin and differentiation state of the tumours. MicroRNAs (miRNAs) are 21–23 nucleotide RNA molecules that regulate the stability or translational efficiency of target messenger RNAs1. miRNAs have diverse functions, including the regulation of cellular differentiation, proliferation and apoptosis2. Although strict tissue- and developmental-stage-specific expression is critical for appropriate miRNA function, mammalian transcription factors that regulate miRNAs have not yet been identified. The proto-oncogene c-MYC encodes a transcription factor that regulates cell proliferation, growth and apoptosis3. Dysregulated expression or function of c-Myc is one of the most common abnormalities in human malignancy4. Here we show that c-Myc activates expression of a cluster of six miRNAs on human chromosome 13. Chromatin immunoprecipation experiments show that c-Myc binds directly to this locus. The transcription factor E2F1 is an additional target of c-Myc that promotes cell cycle progression5,6,7. We find that expression of E2F1 is negatively regulated by two miRNAs in this cluster, miR-17-5p and miR-20a. These findings expand the known classes of transcripts within the c-Myc target gene network, and reveal a mechanism through which c-Myc simultaneously activates E2F1 transcription and limits its translation, allowing a tightly controlled proliferative signal.

15 February 2009 in Nature
Verified
Journal Article
Open access
PDF file
PGPing Gao
Ping Gao
ITIrina Tchernyshyov
Irina Tchernyshyov
TCTsung-Cheng Chang
Tsung-Cheng Chang
YLYun-Sil Lee
Yun-Sil Lee
KKKayoko Kita
Kayoko Kita
CDChi V. Dang
Chi V. Dang
C-Myc is an oncogene involved in many forms of cancer. Proteomic analysis of human P-493 B lymphoma cells and PC3 prostate cancer cells shows that c-Myc regulates the microRNAs miR-23a and miR-23b to increase the expression of the mitochondrial enzyme glutaminase. This leads to enhanced glutamine metabolism and contributes to the metabolic changes in Myc-driven cancers. This paper shows that c-Myc regulates the microRNAs miR-23a and miR-23b to increase the expression of the mitochondrial enzyme glutaminase. This leads to enhanced glutamine metabolism and contributes to the metabolic changes in c-Myc-driven cancers. Altered glucose metabolism in cancer cells is termed the Warburg effect, which describes the propensity of most cancer cells to take up glucose avidly and convert it primarily to lactate, despite available oxygen1,2. Notwithstanding the renewed interest in the Warburg effect, cancer cells also depend on continued mitochondrial function for metabolism, specifically glutaminolysis that catabolizes glutamine to generate ATP and lactate3. Glutamine, which is highly transported into proliferating cells4,5, is a major source of energy and nitrogen for biosynthesis, and a carbon substrate for anabolic processes in cancer cells, but the regulation of glutamine metabolism is not well understood1,6. Here we report that the c-Myc (hereafter referred to as Myc) oncogenic transcription factor, which is known to regulate microRNAs7,8 and stimulate cell proliferation9, transcriptionally represses miR-23a and miR-23b, resulting in greater expression of their target protein, mitochondrial glutaminase, in human P-493 B lymphoma cells and PC3 prostate cancer cells. This leads to upregulation of glutamine catabolism10. Glutaminase converts glutamine to glutamate, which is further catabolized through the tricarboxylic acid cycle for the production of ATP or serves as substrate for glutathione synthesis11. The unique means by which Myc regulates glutaminase uncovers a previously unsuspected link between Myc regulation of miRNAs, glutamine metabolism, and energy and reactive oxygen species homeostasis.

29 July 2016 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
BABrian J. Altman
Brian J. Altman
ZSZachary E. Stine
Zachary E. Stine
CDChi V. Dang
Chi V. Dang